Aviragen Therapeutics, Inc. (NASDAQ:AVIR)‘s stock had its “hold” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Tuesday.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Carlson Capital Management bought a new stake in shares of Aviragen Therapeutics during the second quarter valued at approximately $105,000. Virtu KCG Holdings LLC bought a new stake in shares of Aviragen Therapeutics during the second quarter valued at approximately $149,000. Finally, FMR LLC increased its position in shares of Aviragen Therapeutics by 115.3% during the first quarter. FMR LLC now owns 1,002,500 shares of the biotechnology company’s stock valued at $653,000 after purchasing an additional 536,799 shares during the period. Institutional investors and hedge funds own 24.20% of the company’s stock.
Aviragen Therapeutics Company Profile
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Aviragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.